{"created":"2021-03-01T06:30:57.049279+00:00","id":25476,"links":{},"metadata":{"_buckets":{"deposit":"6221cde2-b8b2-41fc-a36c-f34964cb555d"},"_deposit":{"id":"25476","owners":[],"pid":{"revision_id":0,"type":"depid","value":"25476"},"status":"published"},"_oai":{"id":"oai:niigata-u.repo.nii.ac.jp:00025476","sets":["432:1291:1292:1300","453:456"]},"item_7_alternative_title_1":{"attribute_name":"その他のタイトル","attribute_value_mlt":[{"subitem_alternative_title":"一次性シェーグレン症候群患者の唾液分泌量と唾液成分に対する塩酸セビメリン投与後6ヶ月の効果"}]},"item_7_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2009-06","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"28","bibliographicPageStart":"25","bibliographicVolumeNumber":"39","bibliographic_titles":[{"bibliographic_title":"新潟歯学会雑誌"},{"bibliographic_title":"新潟歯学会雑誌","bibliographic_titleLang":"en"}]}]},"item_7_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"The aim of this study was to clarify pre- and post-cevimeline hydrochloride administrative changes of salivary flow rate and salivary components in primary s Sjögren's syndrome (SS) patients. Twelve females who were diagnosed with primary SS were subjects in this study. Thirty milligrams of cevimeline hydrochloride was administered 3 times daily for 6 months. Whole stimulated saliva was collected from patients before and after administration. MMP (matrix metalloproteinase)-9 was measured by the sandwich-ELISA (enzyme-linked immunosorbent assay) method. The levels of Na^+, Cl^- and K^+ ions were measured by the ISE (ion-selective electrode) method. The level of Ca^<2+> ion was measured by the OCPC (ortho-cresolphthalein-complexone) method and amylase activity was determined by the enzyme coupling method. Whole stimulated saliva secretion was significantly higher (p ＝ 0.034) after administration. Na^+,Cl^-,Ca^<2+> ions and MMP-9 levels were not different after administration. Amylase activity (p ＝ 0.105) and K^+ ion level (p ＝ 0.105) decreased but not significantly after administration. Therefore, Cevimeline hydrochloride at a dosage of 30 mg, 3 times daily may improve some symptoms of xerostomia in patients with primary SS, though there was no change of salivary components.","subitem_description_type":"Abstract"},{"subitem_description":"この研究の目的は一次性シェーグレン症候群患者（pSS）の唾液分泌量と唾液成分に対する塩酸セビメリン投与前後の変化を調べることである。この研究の対象者は一次性pSS患者12 人であった。6ヶ月間1日3回30mgの塩酸セビメリンを投与した。試料としての全唾液は投与前後に集めた。Matrix Metalloproteinase-9（MMP －9）はsandwich-ELISA (enzyme-linked immunosorbent assay)方法で測定した。Na，Cl とKイオンはOCPC (orthocresolphthalein-complexone) 方法で測定し，アミラーゼ活性はEnzyme coupling 法で測定した。その結果，全刺激唾液は投与後で有意に増加した（P ＝ 0.034）。Na，Cl，CaイオンとMMP-9レベルは投与後で変化がみられなかった。アミラーゼ活性（P ＝ 0.105）とK イオンレベル（P ＝ 0.105）は投与後に減少傾向を示したが, 有意差は認められなかった。それゆえ，塩酸セビメリン30mg の1日3回投与によって，一次性シェーグレン症候群患者（pSS）の唾液成分は変化しなかったが，口腔乾燥症状は改善する可能性が示された。","subitem_description_type":"Abstract"}]},"item_7_full_name_3":{"attribute_name":"著者別名","attribute_value_mlt":[{"nameIdentifiers":[{"nameIdentifier":"150205","nameIdentifierScheme":"WEKO"}],"names":[{"name":"船山, さおり"}]},{"nameIdentifiers":[{"nameIdentifier":"150206","nameIdentifierScheme":"WEKO"}],"names":[{"name":"伊藤, 加代子"}]},{"nameIdentifiers":[{"nameIdentifier":"150207","nameIdentifierScheme":"WEKO"}],"names":[{"name":"人見, 康正"}]},{"nameIdentifiers":[{"nameIdentifier":"150208","nameIdentifierScheme":"WEKO"}],"names":[{"name":"佐久間, 汐子"}]},{"nameIdentifiers":[{"nameIdentifier":"150209","nameIdentifierScheme":"WEKO"}],"names":[{"name":"伊藤, 聡"}]},{"nameIdentifiers":[{"nameIdentifier":"150210","nameIdentifierScheme":"WEKO"}],"names":[{"name":"野村, 修一"}]},{"nameIdentifiers":[{"nameIdentifier":"150211","nameIdentifierScheme":"WEKO"}],"names":[{"name":"五十嵐, 敦子"}]}]},"item_7_publisher_7":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"新潟歯学会"}]},"item_7_select_19":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_select_item":"publisher"}]},"item_7_source_id_11":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AN0018300X","subitem_source_identifier_type":"NCID"}]},"item_7_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"03850153","subitem_source_identifier_type":"ISSN"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Funayama, Saori"}],"nameIdentifiers":[{"nameIdentifier":"150198","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ito, Kayoko"}],"nameIdentifiers":[{"nameIdentifier":"150199","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Hitomi, Yasumasa"}],"nameIdentifiers":[{"nameIdentifier":"150200","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Sakuma, Shihoko"}],"nameIdentifiers":[{"nameIdentifier":"150201","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ito, Satoshi"}],"nameIdentifiers":[{"nameIdentifier":"150202","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Nomura, Shuichi"}],"nameIdentifiers":[{"nameIdentifier":"150203","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Igarashi, Atsuko"}],"nameIdentifiers":[{"nameIdentifier":"150204","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2019-08-19"}],"displaytype":"detail","filename":"NS_39(1)_25-28.pdf","filesize":[{"value":"1.0 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"NS_39(1)_25-28.pdf","url":"https://niigata-u.repo.nii.ac.jp/record/25476/files/NS_39(1)_25-28.pdf"},"version_id":"cae309f1-e623-4adb-92fe-e6cd16288706"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Cevimeline hydrochloride","subitem_subject_scheme":"Other"},{"subitem_subject":"primary Sjögren's syndrome","subitem_subject_scheme":"Other"},{"subitem_subject":"Saliva","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Effect of 6-month administration of Cevimeline hydrochloride on salivary flow rate and s alivary components in primary Sjögren's syndrome patients","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Effect of 6-month administration of Cevimeline hydrochloride on salivary flow rate and s alivary components in primary Sjögren's syndrome patients"},{"subitem_title":"Effect of 6-month administration of Cevimeline hydrochloride on salivary flow rate and s alivary components in primary Sjögren's syndrome patients","subitem_title_language":"en"}]},"item_type_id":"7","owner":"1","path":["456","1300"],"pubdate":{"attribute_name":"公開日","attribute_value":"2015-01-21"},"publish_date":"2015-01-21","publish_status":"0","recid":"25476","relation_version_is_last":true,"title":["Effect of 6-month administration of Cevimeline hydrochloride on salivary flow rate and s alivary components in primary Sjögren's syndrome patients"],"weko_creator_id":"1","weko_shared_id":null},"updated":"2022-12-15T03:55:26.123558+00:00"}